retatrutide update ESC 2024: improves lipid and cardiovascular risk profile in Phase II trial ADA 2026: Retatrutide Revolution

Regional support for healthcare advancements and access to innovative therapies further strengthens North Americas position in the market, making it a major contributor to GLP-1 receptor agonist demand

Nutritional risk during GLP-1 therapy is primarily intake-driven rather than malabsorptive in origin

Patients who cannot tolerate one medication often tolerate the other better, so switching is always on the table

A., & Milicevic, Z

"Retatrutide in Patients with NAFLD: A Randomized Phase 2 Trial." Hepatology/AASLD.(Confirms that lower doses are highly effective for metabolic/liver health)

In the GLP-1 context, transfers occur in several scenarios: Lab to new plant: For example, when Lillys new Indiana plant begins making tirzepatide, the established R&D process (including fermentor operating procedures or peptide coupling protocols) must be painstakingly transferred